Research overview: SGLT2 inhibitors for feline diabetes

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, oral drugs that lower blood glucose by promoting urinary glucose excretion, gained approval for treating feline diabetes, offering the first effective oral, non-insulin option and removing the barrier of daily injections for many owners. These agents work independently of insulin, suiting the type 2-like disease, though appropriate case selection and monitoring for euglycemic ketoacidosis are emphasized. This overview synthesizes the pharmacology and clinical literature rather than one citation, describing how SGLT2 inhibition reduces glucose, why an oral option improves treatment acceptance and compliance, and which cats are suitable candidates. It matters because these drugs represent a major practical advance in feline diabetes management, potentially increasing the number of cats that receive effective, sustained treatment for their disease.